Derma Sciences, Organogenesis tout Medicare reimbursement win

Updated to include more information, commentary from Organogenesis. Medicare administrative contractor National Government Services has retired previous coverage policies on cellular and tissue-based products, effective September 1st. The change will allow new coverages and reimbursement through Medicare for such products based on FDA labeling and packaging. Derma Sciences (NSDQ:DSCI and Organogenesis have said the changes will allow for their products to receive coverage and reimbursement for individuals covered under NGS. Approximately 24 million Medicare Part B beneficiaries are covered by NGS, and with the change its Amnioexcel will be eligible for Medicare reimbursement in 47 states and up to 93% of all Medicare beneficiaries. Derma Sciences’ Amnioexcel will now be considered, with appropriate documentation of medical necessity, as a second-line therapy, following standard wound care treatment. “We are very pleased with NGS’ decision to retire its LCD for CTPs. NGS’ jurisdiction includes several major metropolitan areas – such as New York, Boston and Chicago, which not only increases our market for Amnioexcel, but permits much more efficient sales rep coverage. While we now have coverage over the bulk of the country, we continue to pursue an LCD from the remaining MAC for Amnioexcel in order to ensure complete nationwide access to those who suffer from diabetic ulcers and other chronic wounds. Of note, Amnioexcel is one of the only amniotic allo...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news